Mycobacterium smegmatis: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
Shanshan Cen (talk | contribs) |
||
| Line 18: | Line 18: | ||
==Treatment== | ==Treatment== | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
* in vitro | * in vitro <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | ||
:* susceptible: [[Sulfonamides]], [[Doxycycline]], [[Imipenem]], and [[Amikacin]] | :* susceptible: [[Sulfonamides]], [[Doxycycline]], [[Imipenem]], and [[Amikacin]] | ||
* Mild disease | * Mild disease | ||
:* Preferred regimen: [[Doxycycline]] {{and}} [[ | :* Preferred regimen: [[Doxycycline]] {{and}} [[ Trimethoprim sulfamethoxazole]] orally | ||
* Severe disease | * Severe disease | ||
Revision as of 15:20, 7 July 2015
| Mycobacterium smegmatis | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | ||||||||||||
| Scientific classification | ||||||||||||
| ||||||||||||
| Binomial name | ||||||||||||
| Mycobacterium smegmatis (Trevisan 1889) Lehmann & Neumann 1899 |
Mycobacterium smegmatis is an acid-fast bacterial species in the genus Mycobacterium. It was first reported in November 1884 by Lustgarten who found a bacillus with the staining appearance of tubercle bacilli in syphilitic chancres. Subsequently, Alvarez and Tavel found organisms similar to that described by Lustgarten as well as in normal genital secretions (smegma). This organism was later named M. smegmatis.
M. smegmatis is generally considered a non-pathogenic microorganism, however in some cases it can cause disease, mainly in animals.
Treatment
Antimicrobial regimen
- in vitro [1]
- susceptible: Sulfonamides, Doxycycline, Imipenem, and Amikacin
- Mild disease
- Preferred regimen: Doxycycline AND Trimethoprim sulfamethoxazole orally
- Severe disease
References
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.